2020/Rheumatology. 2020 January


Blandine Guffroy, Maxime Ingwiller, Pierre-Edouard Gavand, Bastien Bouldoires, Thierry Krummel, Bruno Lioure, Thierry Martin, Aurélien Guffroy.

SSc is a rare systemic autoimmune disease characterized by microvascular impairment and fibrosis of the skin and other organs, with poor outcomes. Conventional immunosuppressive therapies have a limited impact in diffuse and severe forms of SSc. The best therapeutic strategy to date, demonstrated by two phase III randomized trials, is autologous hematopoietic stem cell transplantation (AHSCT), consisting of immune rebooting with chemotherapy and immune reconstitution by reinjection of autologous hematopoietic stem cells. This procedure requires collection of circulating stem cells after a mobilization step, usually consisting of chemotherapy (often CYC) plus G-CSF stimulation.


Read the article: https://academic.oup.com/rheumatology/advance-article/doi/10.1093/rheumatology/kez662/5709517